Spero Therapeutics, Inc. (SPRO)
2.445
+0.08
(+3.60%)
USD |
NASDAQ |
Jan 22, 16:00
2.445
0.00 (0.00%)
After-Hours: 18:52
Spero Therapeutics Cash from Investing (Quarterly): 0.00 for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | -330.96M |
| Amicus Therapeutics, Inc. | -1.299M |
| Cassava Sciences, Inc. | -0.08M |
| Omeros Corp. | -6.861M |
| GeoVax Labs, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 17.42M |
| Free Cash Flow | -27.67M |
| Free Cash Flow Per Share (Quarterly) | 0.3096 |
| Free Cash Flow to Equity (Quarterly) | 17.69M |
| Free Cash Flow to Firm (Quarterly) | 17.42M |
| Free Cash Flow Yield | -20.37% |